Business Wire

JAMESTOWN

24.2.2021 16:24:06 CET | Business Wire | Press release

Share
Jamestown Expands European Presence With More Than $1 Billion in Assets Under Management

Global real estate and investment company Jamestown today announced it has significantly expanded its global presence and now has more than $1 billion in European assets under management with the acquisition of another two buildings in Amsterdam, and a mandate to manage a portfolio of properties across Europe on behalf of one of its institutional investment partners and co-investors, E.ON Pension Trust. This latest news about its European portfolio comes on the heels of Jamestown’s recent purchase of three office buildings in Cologne, Germany, and just over a year after purchasing the iconic Groot Handelsgebouw in Rotterdam, one of the largest mixed-use buildings in the Netherlands, which currently houses more than 450 businesses.

“After entering the European market just over a year ago, Jamestown has grown its platform with $1 billion in assets under management and a knowledgeable real estate team headquartered in Cologne, Germany and offices in Amsterdam, London, and Madrid,” said Jamestown president Michael Phillips. “We continue to see many opportunities for future growth. Our vertically integrated team structure is at the root of our value-add asset management strategy enabling us to create innovative spaces while simultaneously preserving cities’ industrial pasts. As our European footprint expands, we will continue to focus on sustainable, adaptive reuse projects that bring new life to local communities.”

Jamestown’s newly acquired Dutch assets are in Amsterdam’s up-and-coming Schinkel neighborhood and include the historic A-Factorij, previously owned by E.ON Pension Trust and home to one of Jamestown’s European offices, and Helicopterstraat, a property previously owned by Gerose and comprised of four buildings on the adjoining Helicopterstraat, Vliegtuigstraat, and Valschermkade. The properties were acquired in partnership with E.ON Pension Trust and the RAG-Stiftung. E.ON Pension Trust made the decision to include A-Factorij in the co-investment given their belief in the long-term potential of the neighborhood, and that future opportunities in the neighborhood with the newly acquired properties are better acted on as co-investors.

In addition, Jamestown will provide asset management services for a portfolio of properties owned by E.ON Pension Trust in Italy, the Netherlands, Portugal, Spain, and the UK. The properties Jamestown will manage include a mix of shopping centers, office buildings, and mixed-use developments.

“We have known Jamestown for a long time and they have been a great partner to us in the US,” said Udo Schaffer, Vice President, Head of Real Estate, E.ON SE. “Jamestown is one of our preferred global partners given their active approach to asset management and focus on creative and out-of-the-box thinking. After several co-investments with Jamestown in Europe, we now look forward to working with them on the E.ON Pension Trust Separate Account Portfolio.”

A-Factorij (Pilotenstraat 35-45), a 128,177 square foot / 11,908 square meter former bicycle factory was originally built in 1955 and converted into a creative office space in 2002. Jamestown has been involved in management of the property since 2018. Adjacent to A-Factorij is Helicopterstraat, a 67,102 square foot / 6,234 square meter commercial property comprising four interconnected offices and industrial space, with a showroom and gym on the ground floor. The Schinkel district is transforming from industrial and loft offices to a true mixed-use community with a residential focus. The Amsterdam municipality plans to turn the 247-acre neighborhood into a vibrant, innovative, and sustainable district with international allure.

Gerose was represented by Appelhoven Real Estate Advisors in this off-market transaction.

Van Ooijen Accountants & Tax Advisors (Paul van der Aar and Adriaan Daniels) were the legal & tax advisors of the seller, together with HMK Notarissen. Greenberg Traurig represented Jamestown.

“This area of Amsterdam has generated a lot of interest from institutional and private investors from around the world,” said Stijn Uijthoven of Appelhoven Real Estate Advisors. “The properties Jamestown has acquired from Gerose Vastgoed were designed to be flexible and sustainable, and responsive to the changing neighborhood. It was a pleasure to work with Jamestown on this transaction and I look forward to seeing the evolution of the properties and the larger community in the coming years.”

Jamestown has a long-standing commitment to securing a better future for its tenants, residents, visitors, and investors by creating spaces that are sustainable, healthy, and inclusive. In 2020, after achieving its goal to reduce energy and greenhouse gas (GHG) emissions by 20 percent four years ahead of schedule, Jamestown committed to reducing its GHG emissions once again by committing to achieve net zero operational carbon by 2050. Jamestown also joined the ranks of other forward-thinking global organizations and 193 countries, and has adopted the United Nations Sustainable Development Goals into its corporate sustainability strategy.

For high-resolution images of A-Factorij and Helicopterstraat, please click here .

About Jamestown

Jamestown is a design-focused real estate investment and management company with a 37-year track record and a clear mission: to transform spaces into innovation hubs and community centers. Jamestown employs more than 400 people worldwide with headquarters in Atlanta, Georgia, and Cologne, Germany, and offices in Amsterdam, Bogotá, Boston, London, Los Angeles, Madrid, New York, and San Francisco. The company is well-known in the industry for its market discipline. Since its founding in 1983, Jamestown has executed transactions in excess of $35 billion, and as of December 31, 2020, the company has assets under management of $12.1 billion. Current and previous iconic projects include Chelsea Market in New York City, Industry City in Brooklyn, Ponce City Market in Atlanta, Ghirardelli Square in San Francisco, and the Innovation and Design Building in Boston. In addition to its portfolio in key markets throughout the U.S., Jamestown continues to expand its investment footprint to South America and Europe.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye